Nilesh Patel
Direttore/Membro del Consiglio presso Cellanyx Diagnostics LLC
Profilo
Nilesh Patel is currently working as a Director at Cellanyx Diagnostics LLC.
He completed his undergraduate degree from Indian Institute of Technology Bombay and his MBA from Columbia Business School.
Posizioni attive di Nilesh Patel
| Società | Posizione | Inizio |
|---|---|---|
Cellanyx Diagnostics LLC
 Cellanyx Diagnostics LLC Medical SpecialtiesHealth Technology Cellanyx Diagnostics LLC is a company that is developing a cancer testing platform to aid clinical decision-making. The company is based in Beverly, MA and was founded by Ashok Chander and Michael Manak. The company's technology provides quantitative assessments of individual cancer cells in biopsy samples using multiple biochemical and biophysical markers of tumor aggressiveness and metastatic potential. The company has demonstrated clinical proof-of-concept with their lead test in development, which aims to improve risk stratification in men with prostate cancer. | Direttore/Membro del Consiglio | 19/01/2021 |
Formazione di Nilesh Patel
| Columbia Business School | Masters Business Admin |
| Indian Institute of Technology Bombay | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Cellanyx Diagnostics LLC
Cellanyx Diagnostics LLC Medical SpecialtiesHealth Technology Cellanyx Diagnostics LLC is a company that is developing a cancer testing platform to aid clinical decision-making. The company is based in Beverly, MA and was founded by Ashok Chander and Michael Manak. The company's technology provides quantitative assessments of individual cancer cells in biopsy samples using multiple biochemical and biophysical markers of tumor aggressiveness and metastatic potential. The company has demonstrated clinical proof-of-concept with their lead test in development, which aims to improve risk stratification in men with prostate cancer. | Health Technology |
- Borsa valori
- Insiders
- Nilesh Patel
